Navigation Links
Molecule linked to aggressive pancreatic cancer offers potential clinical advances
Date:5/20/2014

JACKSONVILLE, Fla. Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

They say the study, published in Molecular Cancer Research, provides key insights into the most aggressive form of the disease, which is one of the deadliest human cancers.

It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b.

"The implication from our research is that Rac1b is activating unique pathways in pancreatic tumors that make this cancer aggressive. If we can therapeutically target that pathway, we may be able to have an impact on this very difficult-to-treat disease," says the study's senior investigator, Derek Radisky, Ph.D., a researcher with the Mayo Clinic Cancer Center in Jacksonville, Fla.

A potential drug target would have to be found within the cancer-causing pathways activated by Rac1b, since the enzyme is difficult to target because it is involved in many normal biological processes, Dr. Radisky says. He and his colleagues are now working to uncover how Rac1b ramps up pancreatic cancer progression.

The RAC1 superfamily of proteins which play important regulatory roles in cell growth and cell movement have been implicated in other cancers, such as melanoma and non-small cell lung cancer, but before this study, no one knew that one sub-form, Rac1b, played a role in pancreatic cancer.

The research team includes investigators from Mayo Clinic in Florida and Mayo Clinic SPORE in Pancreatic Cancer, one of three cancer centers in the U.S. to receive a Specialized Program of Research Excellence (SPORE) grant for pancreatic cancer from the National Cancer Institute. The Pancreatic Cancer SPORE is specifically committed to reducing the incidence and mortality of pancreatic cancer. The team began their research by investigating why pancreatic cancer cells produce matrix metalloproteinases (MMPs), enzymes that break down the sticky adhesion molecules that keep cells glued together in a tissue, or in a tumor. MMPs allow cancer cells to migrate away from a tumor.

"Most MMPs are made by cells that surround and support a tumor, not by the tumor itself, as we see in pancreatic cancer," Dr. Radisky says.

Using a combination of human tissue biopsies, novel transgenic animal models and cell culture studies, the researchers established a link between expression of MMP3 and activation of Rac1b. Then, using Mayo Clinic's large panel of human pancreatic cancer biopsies, the scientists found that expression levels of Rac1b were significantly associated with the cancer's prognosis.

The researchers verified their findings by treating cultured pancreatic cancer cells with recombinant MMP3. They found this was sufficient to induce Rac1b and increased cancer invasiveness.

"Pancreatic cancer is not uniformly aggressive some patients have a relatively better outcome. This work allows us to hone in on those patients who don't do as well, and who would most benefit from more targeted therapies," Dr. Radisky says.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Molecules involved in rheumatoid arthritis angiogenesis identified
2. Protein molecule may improve survival in deadly lung disease
3. Faster dental treatment with new photoactive molecule
4. Discovery of anti-appetite molecule released by fiber could help tackle obesity
5. Alcohol-breakdown molecule may play a role in breast cancer development
6. Designer swiss-army-knife molecule captures RNA in single cells in their natural tissue environment
7. Molecule discovered that protects the brain from cannabis intoxication
8. Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both
9. Immune system molecule promotes tumor resistance to anti-angiogenic therapy
10. A new method for clicking molecules together
11. Metabolic molecule drives growth of aggressive brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical Director ... their drug rehab center in Delray Beach, Florida has been changed from Sober Living ... such as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but ...
(Date:1/19/2017)... ... 2017 , ... WhoHaha , a digital media company dedicated to creating ... to produce a three-part video series that uses humor to highlight ways to improve ... of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery community, begins ... make it easier for their readers to get the information they desire. The procedures ... as the techniques used on those particular areas. , “We are excited to streamline ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it will be ... leader in innovative excipients and drug delivery solutions to health industries worldwide. The ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... , Jan. 18, 2017 The ... Food and Drug Administration (FDA) for its release ... and population health decision makers can proactively share ... products as well as emerging therapies awaiting FDA ... mirrors consensus recommendations that AMCP developed during two ...
Breaking Medicine Technology: